Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate
University of Ottawa · Bristol-Myers Squibb (United States) · +12 more institutions
Abstract
To validate and compare the definition of the Disease Activity Score 28 based on C-reactive protein (DAS28 (CRP)) to the definition based on erythrocyte sedimentation rate (ESR).
Data were analysed from two randomised, double-blind, placebo-controlled trials of abatacept of 6-month and 12-month duration in patients with rheumatoid arthritis. European League Against Rheumatism (EULAR) response criteria and the proportion of patients in remission (DAS28
Citation impact
- FWCI
- 11.81
- Percentile
- 100%
- References
- 29
Authors
8- GAGeorge A. WellsCorresponding
University of Ottawa
- JBJ-C Becker
Bristol-Myers Squibb (United States), Bristol-Myers Squibb (Germany)
- JTJ. Teng
Bristol-Myers Squibb (Germany), Bristol-Myers Squibb (United States)
- MDMaxime Dougados
Assistance Publique – Hôpitaux de Paris, Université Paris Cité, Délégation Paris 5, Hôpital Cochin
- MSMichael Schiff
University of Colorado System, University of Colorado Denver
Topics & keywords
- Medicine
- Rheumatism
- Erythrocyte sedimentation rate
- Rheumatoid arthritis
- Internal medicine
- Abatacept
- Physical therapy
- Placebo